GEFZEST 250 TABLETS

GEFZEST 250 Tablets are a prescription-targeted anticancer therapy containing gefitinib, an EGFR tyrosine kinase inhibitor used for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC). This oral medicine is designed to target cancer at the molecular level, making it an important option in modern lung cancer treatment.

Gefitinib in GEFZEST works by blocking EGFR signaling pathways that drive cancer cell growth, division, and spread. Inhibiting these abnormal signals, it helps slow tumor progression and supports better disease control. The convenient oral tablet form allows for effective long-term targeted therapy as prescribed by an oncologist.

This product ensures consistent quality, safety, and therapeutic efficacy. It is a prescription-only oncology medicine intended for oral use and must be taken strictly under the supervision of a qualified oncologist. GEFZEST provides a reliable treatment option for patients with EGFR-positive NSCLC, supporting targeted cancer management.

Product Features

• Orally targeted anticancer tablets
• Contains Gefitinib 250 mg
• EGFR tyrosine kinase inhibitor
• Used in EGFR-positive NSCLC
• High-specificity targeted therapy
• Once-daily oral dosage
• Manufactured under GMP-compliant standards
• Prescription-required oncology medicine

How It Helps

• Blocks EGFR signaling pathways to inhibit cancer cell growth
• Helps slow the progression of EGFR mutation-positive lung cancer
• Targets cancer cells while sparing normal cells
• Supports effective oral targeted therapy under the oncologist’s supervision